Compare RCON & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RCON | GRML |
|---|---|---|
| Founded | 2007 | N/A |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 34.9M |
| IPO Year | 2008 | 2022 |
| Metric | RCON | GRML |
|---|---|---|
| Price | $0.44 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.3K | ★ 3.3M |
| Earning Date | 03-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,430,788.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.21 |
| 52 Week High | $7.16 | $0.55 |
| Indicator | RCON | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 33.51 |
| Support Level | N/A | $0.21 |
| Resistance Level | $0.63 | $0.34 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 15.86 | 16.57 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.